Please assess the completion status of the following clinical trial:

Trial Title: Cognitive and Psychophysiological Effects of Delta-9-Tetrahydrocannabinol in Bipolar Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria for individuals with Bipolar Disorder (BD)~1. Men and women aged 18-55 years (extremes included).~2. Able to provide informed consent in English.~3. A diagnosis of BD type I or BD type II and good physical health.~4. Current euthymic state for at least 4 weeks.~Inclusion Criteria for Healthy Control (HC) individuals:~1. Men and women aged approximately 18-55 years (extremes included).~2. Able to provide informed consent in English.~3. No psychiatric diagnoses and in good physical health.~General exclusion criteria:~1. Cannabis naïve~2. Unwillingness to remain alcohol-free, cannabis-free for at least 1 week (in infrequent cannabis users) prior to each test day.~3. Evidence of a hearing deficit.~4. IQ less than 80.~5. Positive pregnancy test, lactation, and refusal to practice birth control.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Active 4 mg inhaled THC (Type: EXPERIMENTAL): Subject will have 1/3 chance of receiving 4 mg THC administered through a vaporizer, over approximately 20 minutes, followed by approximately 45 minutes of neuropsychological and physiological testing.
- Active 2 mg inhaled THC (Type: EXPERIMENTAL): Subject will have 1/3 chance of receiving 2 mg THC administered through a vaporizer, over approximately 20 minutes, followed by approximately 45 minutes of neuropsychological and physiological testing.
- Placebo (Type: PLACEBO_COMPARATOR): Subject will have 1/3 chance of receiving the inhaled placebo condition administered through a vaporizer, over approximately 20 minutes, followed by approximately 45 minutes of neuropsychological and physiological testing. The placebo condition will include no active cannabinoids.

Based on this trial design, predict the completion outcome and termination type (if applicable).